
Summit launches Phase III lung cancer trial for ivonescimab
Key points
- Summit Therapeutics launched HARMONi-10, a global Phase III trial comparing its experimental drug ivonescimab with durvalumab in patients with unresectable Stage III non-small cell lung cancer.
- The trial will compare the treatments as consolidation therapy following concurrent platinum-based chemoradiation, with progression-free survival as its primary endpoint.
- HARMONi-10 is Summit's sixth sponsored Phase III study of ivonescimab, expanding its clinical development programme into earlier-stage lung cancer, with global trial site activations expected to begin in the fourth quarter of 2026.
Summit Therapeutics (NASDAQ:SMMT) launched HARMONi-10, a global Phase III trial comparing its experimental drug ivonescimab with durvalumab in patients with unresectable Stage III non-small cell lung cancer.
The study will evaluate the treatments as consolidation therapy following platinum-based concurrent chemoradiation, a setting where durvalumab is an established standard of care.
"HARMONi-10 is the next bold step in a clinical development program built to change what is possible for people with lung cancer," said Robert W. Duggan, chairman and co-chief executive officer of Summit Therapeutics.
The open-label, multi-regional study will use progression-free survival as its primary endpoint, with global clinical trial site activations expected to begin in the fourth quarter of 2026.
In premarket trading on November 18, Summit shares were quoted at $10.31, down approximately 3.4% from the previous closing price of $10.67.
The announcement follows the US Food and Drug Administration's November 16 decision to issue a Complete Response Letter for a separate ivonescimab application involving previously treated patients with advanced non-small cell lung cancer, citing insufficient evidence of a statistically significant overall survival benefit.
HARMONi-10 is Summit's sixth sponsored Phase III study of ivonescimab and its fourth in non-small cell lung cancer, while the drug remains investigational in Summit's licensed territories, including the United States and Europe, despite receiving approval in China in May 2024.


